TEAD transcription factors act as the principal downstream mediators of Hippo signaling. In many cancers, dysregulated Hippo-TEAD activity drives cell proliferation, survival programs, and maladaptive tissue growth. Although the TEAD node has been widely viewed as a compelling target, historically, creating selective, drug-like small molecules that effectively inhibit TEAD has been difficult from a medicinal chemistry perspective.

ISM6331 is designed to inhibit TEAD activity using Insilico Medicine’s generative AI-powered discovery platform, Chemistry42. The company describes the compound as a novel and potent pan-TEAD inhibitor, with the goal of achieving selective suppression of pan-TEAD transcriptional signaling. This focus on the TEAD transcription machinery reflects a broader shift in oncology drug development toward pathway-level control rather than single-protein inhibition.

The study being presented is a global, multicenter Phase 1 trial enrolling patients with mesothelioma and other advanced solid tumors. Investigators are evaluating safety and tolerability, along with pharmacokinetics, to characterize exposure and dose behavior. In parallel, the trial includes preliminary assessments of antitumor activity to inform future expansion cohorts and development decisions.

For oncology patients with limited options—particularly in hard-to-treat indications such as malignant mesothelioma—early clinical signals can carry high relevance. Insilico’s leadership emphasized that the selection of ISM6331 for a Rapid Oral slot reflects confidence in the early translational value of the program.

Beyond the molecule itself, the announcement underscores Insilico’s broader strategy: connecting biology, chemistry, and clinical trial outcome prediction through modern machine learning systems. The company frames Chemistry42 as a key component of an end-to-end generative workflow, including target-inspired design and optimization.

If the Phase 1 results demonstrate acceptable safety and meaningful biological activity, ISM6331 could extend TEAD inhibition from preclinical promise into clinical validation. The ESMO Rapid Oral format also suggests that the dataset may include timely, decision-relevant findings for the field.

In summary, ISM6331’s ESMO 2026 Rapid Oral acceptance spotlights a TEAD-centered Hippo pathway program built with generative AI and moving into clinical interpretation. The upcoming presentation will be closely watched by researchers seeking actionable evidence that AI-guided small-molecule design can overcome longstanding constraints in TEAD inhibitor development.

Subject of Research: Hippo signaling / TEAD transcription factors; oncology drug discovery; mesothelioma and advanced solid tumors
Article Title: Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors
News Publication Date: 2026 (exact date not provided)
Web References: https://www.insilico.com/
References: None provided
Image Credits: Credit: Insilico Medicine

Keywords: Insilico Medicine, ISM6331, pan-TEAD inhibitor, Hippo pathway, TEAD transcription factors, Chemistry42, Phase 1 trial, ESMO 2026, mesothelioma, advanced solid tumors, generative AI drug discovery

At the heart of this resistance lies the tumor microenvironment (TME)—a highly intricate and dynamic assembly of cellular and molecular components that collectively inhibit effective immune attack. This hostile environment is characterized by a predominance of inhibitory signals that effectively mute T cell activity, while the co-stimulatory cues necessary to sustain immune cell function are either markedly diminished or absent. Engineered T cells, including CAR-T therapies, rely heavily on these environmental signals to maintain their activation, proliferation, and cytotoxic functions. Without adequate stimulatory inputs, these cells become exhausted or anergic, thereby failing to eradicate tumor cells effectively. Overcoming this barrier entails designing innovative strategies to equip T cells with synthetic receptors capable of directly sensing and responding to these tumor-specific cues, effectively bypassing the suppressive signals.

In an ambitious stride toward conquering this hurdle, a research team led by Patrick Barth at EPFL and Caroline Arber at UNIL-CHUV has harnessed the power of computational protein engineering to create synthetic receptors from first principles. These proprietary receptor constructs, dubbed T-SenSERs (tumor microenvironment-sensing switch receptors), have been engineered to detect soluble molecular cues prevalent within the TME and translate these signals into co-stimulatory or cytokine-like outputs that potentiate T cell activation. By integrating these synthetic receptors with CAR-T cells, the hybrid immune cells exhibit enhanced anti-tumor efficacy, as demonstrated in preclinical models of lung cancer and multiple myeloma.

The research, recently published in Nature Biomedical Engineering, introduces an inventive computational platform designed to assemble synthetic receptor proteins modularly—akin to constructing intricate architectures with molecular Lego blocks. Each receptor is composed of distinct functional domains meticulously optimized for their roles: an extracellular ligand-binding domain that recognizes tumor-associated soluble factors, a transmembrane segment that efficiently conveys conformational signals across the lipid bilayer, and an intracellular effector domain that initiates desired signaling cascades within the T cell cytoplasm. This modular design framework permits unprecedented customization of receptor function and specificity.

A striking innovation of Barth and colleagues’ computational platform is its dynamic modeling of proteins as flexible, shape-shifting entities rather than static structures. This approach enables in silico visualization of signal propagation through receptor domains, providing critical insight into how engineered receptors can transduce external ligand engagement into precise intracellular responses. This conceptual leap departs from conventional rigid-body approximations, allowing for a more nuanced understanding and predictive control over receptor function, ultimately accelerating the design cycle and enhancing receptor efficacy before bench validation.

The researchers utilized this framework to engineer and refine two distinct classes of T-SenSERs. The first set targets vascular endothelial growth factor (VEGF), a soluble protein extensively secreted by tumors to stimulate angiogenesis, creating new blood vessel networks that facilitate tumor growth and metastasis. The second class detects colony-stimulating factor 1 (CSF1), a modulator known to reprogram immune cell behavior in the TME, often fostering immunosuppression. By generating 18 receptor variants through computational prediction and experimental screening, the team isolated candidates displaying optimal ligand sensitivity, basal activity, and signaling outputs.

Functional assays confirmed that T cells co-expressing both CARs and T-SenSERs manifested augmented tumor recognition and killing capabilities compared to CAR-T cells alone. The VEGF-responsive receptor variant—designated VMR—remained quiescent in the absence of VEGF but triggered robust intracellular activation upon ligand binding. Conversely, the CSF1-responsive receptor, termed CMR, exhibited a nuanced signaling profile with a modest basal activity that intensified in the presence of its ligand. These differential activation patterns illustrate the fine-tuned programmability achieved through computational design, enabling tailoring of receptor responsiveness to the unique biochemical landscape of individual tumors.

In vivo investigations in murine lung cancer and myeloma models provided compelling evidence of the therapeutic advantage conferred by T-SenSER-modified T cells. These engineered cells demonstrated superior tumor growth suppression and extended animal survival relative to controls. The ability to harness and amplify endogenous tumor-derived signals to orchestrate T cell function unveils a promising frontier for improving the clinical efficacy of CAR-T therapies against refractory solid tumors.

Beyond therapeutic outcomes, this study highlights the profound potential of computational design to customize receptor signaling modalities. Researchers can now dictate whether receptors function as strictly ligand-gated switches, constitutively active units, or intermediates featuring graded responses—all encoded at the protein design stage. This capability lays the foundation for next-generation synthetic biosensors capable of complex, context-dependent cellular programming within hostile microenvironments.

Barth emphasizes that these findings represent the inaugural demonstration of single-pass, multi-domain receptors engineered with programmable signal transduction activities via computational means. This pioneering platform not only accelerates the generation of synthetic receptors for cancer immunotherapy but also offers broad applicability for creating bespoke biosensors in cell engineering initiatives across diverse biomedical fields.

Collaborators contributing to this groundbreaking work include leading institutions such as the Ludwig Institute for Cancer Research, Baylor College of Medicine, Swiss Cancer Center Leman, and AGORA Cancer Research Center, underscoring the interdisciplinary and international nature of this endeavor.

This extraordinary advance signals a paradigm shift in cancer immunotherapy by enabling engineered T cells to autonomously sense the tumor milieu and modulate their activity dynamically. As synthetic biology converges with computational modeling, the dream of universally effective solid tumor immunotherapies draws closer to reality, promising new hope for patients battling some of the most intractable cancers.

Subject of Research: Computational design of synthetic protein receptors to enhance cancer T cell therapy by sensing tumor microenvironment signals.

Article Title: Computational design of synthetic receptors with programmable signalling activity for enhanced cancer T cell therapy.

News Publication Date: 28 October 2025

Web References: https://www.nature.com/articles/s41551-025-01532-3

References: Jan A. Rath, Lucas S. P. Rudden, Nazila Nouraee, Tiffany X. Y. Que, Christine Von Gunten, Cynthia Perez, Flora Birch, Yashashvi Bhugowon, Andreas Fueglistaler, Aisima Chatzi Souleiman, Patrick Barth, Caroline Arber. Nature Biomedical Engineering, 28 October 2025. DOI: 10.1038/s41551-025-01532-3

Keywords: Cancer immunotherapy, CAR-T cells, synthetic receptors, tumor microenvironment, computational protein design, T-SenSER, VEGF, CSF1, synthetic biology, protein engineering, solid tumors, programmable signaling.

Fas Ligand (FasL), a protein expressed on the surface of activated immune cells, is a critical mediator of apoptosis, or programmed cell death. This process, indispensable for immune cells, allows them to identify and induce death in cells that are damaged or malignant. Among these immune warriors are CAR-T cells, a form of adoptive cell therapy engineered from the patient’s own immune system, which utilize FasL to trigger apoptosis in cancer cells. Yet, despite remarkable success against hematologic malignancies, CAR-T cell therapies have struggled to replicate such efficacy in solid tumors. The mystery behind this discrepancy now finds a compelling explanation rooted in evolutionary biology.

The team at UC Davis discovered that a single amino acid substitution in the human FasL protein — where serine replaces proline at position 153 — renders FasL highly susceptible to cleavage by plasmin. Plasmin is a proteolytic enzyme abundantly present within the microenvironments of aggressive solid tumors, including triple-negative breast cancer, colon cancer, and ovarian cancer. Through enzymatic cleavage, plasmin effectively disables FasL, neutralizing a key mechanism by which immune cells eliminate cancer cells. This evolutionary mutation appears unique to humans, as FasL in non-human primates such as chimpanzees retains proline at this position, making them less vulnerable to plasmin’s disruptive effects.

From an evolutionary perspective, this mutation in FasL might have been a trade-off that facilitated the development of larger, more complex human brains by modulating immune pathways, particularly pathways involved in cell death. However, in the context of oncology, this beneficial mutation for brain development becomes detrimental. By weakening FasL’s integrity, tumors exploit this vulnerability to disarm one of the immune system’s vital weapons, thus promoting immune evasion and enabling tumor progression and metastasis.

The study’s experimental investigations demonstrated that human immune cells, despite being activated and primed to attack cancer cells, often find their FasL function compromised within plasmin-rich tumor microenvironments. This discovery elegantly explains the limited success of immunotherapies like CAR-T and T-cell-based therapies in solid tumors, which are frequently characterized by an elevated presence of plasmin. In contrast, blood cancers, typically devoid of such high plasmin levels, are more susceptible to FasL-mediated immune eradication, accounting for the pronounced effectiveness of these therapies in hematologic malignancies.

Perhaps the most promising aspect of the UC Davis research lies in its therapeutic implications. By introducing plasmin inhibitors or developing antibodies engineered to shield FasL from plasmin-mediated cleavage, it is now conceivable to protect and restore FasL’s apoptotic function within the hostile solid tumor microenvironment. Such interventions could dramatically enhance the cytotoxic capabilities of immune cells, thereby potentiating immunotherapy responses in cancers that have previously been refractory to treatment.

Importantly, the research underscores a nuanced evolutionary dimension to cancer immunology, suggesting that intricate genetic variations shaped by millions of years of human development bear profound consequences for disease vulnerabilities. The authors emphasize the remarkable difference in cancer incidence and immune system efficacy between humans and their closest evolutionary relatives, primates, and invite deeper comparative study that may unlock further therapeutic avenues.

This breakthrough also challenges the oncology field to reconsider how immune escape mechanisms are understood and addressed. Rather than focusing solely on tumor cell mutations or immune checkpoint pathways, attention must now turn toward these evolutionary genetic alterations within key immune proteins and their interactions with the tumor milieu. Integrating such insights into the design of next-generation immunotherapies could bring personalized and more effective cancer treatments closer to reality.

As the researchers pursue further preclinical and clinical validation of their findings, the overall aim remains clear: to overcome the immunosuppressive tactics of plasmin-positive solid tumors by fortifying the immune system’s molecular arsenal. Should plasmin inhibition or FasL protection prove successful in human trials, it may usher in an unprecedented era of immunotherapy—one that can unlock durable and powerful anti-cancer responses in diverse solid tumors.

The implications of this discovery extend beyond oncology into the broader realm of immunobiology and evolutionary medicine. It highlights how evolutionary gains, such as those enabling cerebral complexity, can inadvertently introduce vulnerabilities in immune defense. Understanding these evolutionary trade-offs not only expands scientific knowledge but also guides the rational development of innovative therapies that reconcile our biological heritage with contemporary medical needs.

In conclusion, the identification of plasmin-mediated FasL inactivation as a unique human evolutionary vulnerability opens an exciting frontier in cancer research. It champions a paradigm wherein evolutionary biology informs precision medicine and offers hope for patients grappling with hard-to-treat solid tumors. As the research community embraces this knowledge, the prospect of more potent, personalized immunotherapies grows ever brighter, signaling a promising shift in the war against cancer.

Subject of Research: People

Article Title: Evolutionary regulation of human Fas ligand (CD95L) by plasmin in solid cancer immunotherapy

News Publication Date: 1-Jul-2025

Web References:

• UC Davis Comprehensive Cancer Center
• Original Study in Nature Communications

References:

• Tushir-Singh, J. et al. Evolutionary regulation of human Fas ligand (CD95L) by plasmin in solid cancer immunotherapy. Nature Communications (2025). https://doi.org/10.1038/s41467-025-60990-0

Keywords:
Cancer research, Cancer, Cancer cells, Cancer immunotherapy, Primates, Nonhuman primates